MDM2 copy numbers in well-differentiated and dedifferentiated liposarcoma

American Journal of Clinical Pathology

Volumn 141, Issue 3, 2014, Pages 334-341

  Ware, Patrick L ^a   Snow, Anthony N ^b   Gvalani, Maya ^a   Pettenati, Mark J ^a   Qasem, Shadi A ^a,c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Dedifferentiated liposarcoma; .; FISH; MDM2; Well differentiated liposarcoma

Indexed keywords

PROTEIN MDM2; MDM2 PROTEIN, HUMAN; TUMOR MARKER;

ABDOMINAL TUMOR; ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DEDIFFERENTIATED LIPOSARCOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RETROPERITONEAL TUMOR; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; WELL DIFFERENTIATED LIPOSARCOMA; CELL DIFFERENTIATION; COPY NUMBER VARIATION; DISEASE COURSE; FISH; GENETICS; LIPOSARCOMA; MDM2; MIDDLE AGED; PATHOLOGY; VERY ELDERLY; WELL-DIFFERENTIATED LIPOSARCOMA;

DEDIFFERENTIATED LIPOSARCOMA; FISH; MDM2; WELL-DIFFERENTIATED LIPOSARCOMA;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; LIPOSARCOMA; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL;

EID: 84897952479     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPLYU89XHSNHQO     Document Type: Article

References (15)

1. Binh MB, Sastre-Garau X, Guillou L, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol. 2005;29:1340-1347.
2. Weaver J, Downs-Kelly E, Goldblum JR, et al. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol. 2008;21:943-949.
3. Coindre JM, Pedeutour F, Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch. 2010;456:167-179.
4. Louis-Brennetot C, Coindre JM, Ferreira C, et al. The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors. Genes Chromosomes Cancer. 2011;50:896-907.
5. Aleixo PB, Hartmann AA, Menezes IC, et al. Can MDM2 and CDK4 make the diagnosis of well differentiated/ dedifferentiated liposarcoma? an immunohistochemical study on 129 soft tissue tumours. J Clin Pathol. 2009;62:1127-1135.
6. Shimada S, Ishizawa T, Ishizawa K, et al. The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers. Hum Pathol. 2006;37:1123-1129.
7. Tap WD, Eilber FC, Ginther C, et al. Evaluation of welldifferentiated/de-differentiated liposarcomas by highresolution oligonucleotide array-based comparative genomic hybridization. Genes Chromosomes Cancer. 2011;50:95-112.
8. Horvai AE, DeVries S, Roy R, et al. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. Mod Pathol. 2009;22:1477-1488.
9. Miura Y, Keira Y, Ogino J, et al. Detection of specific genetic abnormalities by fluorescence in situ hybridization in soft tissue tumors. Pathol Int. 2012;62:16-27.
10. Kashima T, Halai D, Ye H, et al. Sensitivity of MDM2 amplification and unexpected multiple faint alphoid 12 (alpha 12 satellite sequences) signals in atypical lipomatous tumor. Mod Pathol. 2012;25:1384-1396.
11. Henricks WH, Chu YC, Goldblum JR, et al. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol. 1997;21:271-281.
12. Dei Tos AP. Liposarcoma: new entities and evolving concepts. Ann Diagn Pathol. 2000;4:252-266.
13. Mussi C, Collini P, Miceli R, et al. The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution. Cancer. 2008;113:1657-1665.
14. Smith CA, Martinez SR, Tseng WH, et al. Predicting survival for well-differentiated liposarcoma: the importance of tumor location. J Surg Res. 2012;175:12-17.
15. Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013;31:2024-2028.